KR20060081279A - Pharmaceutical composition comprising the extract of bamboo leaf for treating and preventing the mental disease related to cranial nervous system - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for the prevention and treatment of cerebral nervous system-related mental diseases, including bamboo leaf extract, in detail, the bamboo leaf extract of the present invention prevents and treats anxiety, depression and neurological hypersensitivity due to abnormalities of the brain nervous system. It can be used for medicines and dietary supplements.

Bamboo Leaf, Mental Illness, Anxiety, Depression, Neurosensitivity, Health Food

Description

Pharmaceutical composition comprising the extract of Bamboo leaf for treating and preventing the mental disease related to cranial nervous system}             

1 is a view showing the change in staying time in the closed and open space by the administration of bamboo leaf extract in the elevated plus-maze,

2 is a view showing the change in the number of entry and exit of the closed space and the open space by administration of the bamboo leaf extract in the elevated cruciform maze.

The present invention relates to pharmaceutical compositions and health functional foods for the treatment and prevention of cerebral nervous system-related mental diseases containing bamboo leaf extract.

In recent years, anxiety and depression have been increasing in relation to rapidly changing family relationships and economic recession due to divorce. Anxiety is a widespread very unpleasant and vaguely disturbing feeling that is accompanied by physical symptoms such as palpitations, sweating, and behavioral symptoms such as irritability and seodam. The number of patients receiving cancer increased year by year, and in 2002, the sales of anti-anxiety drugs increased by about 200%. It is no exaggeration to say that depression or anxiety can account for most of the mental disorders of modern people, and many suffer from it (Robert. F. Scmidt. Human physiolog y, p366; SV, Pharmacol. Ther ., 88, pp 213-227, 2000).

When there is anxiety, the entire brain enters an arousal state, which impairs peripheral behavior, autonomic nervous system, sensations, and perception. Related organs include the cerebral limbic system (especially the hippocampus and the subject society), the cerebral cortex (frontal and temporal lobes), the hypothalamus, the ascending reticular body and the pituitary gland, and peripheral organs such as the thyroid and adrenal cortex. Recent brain imaging studies have shown that anxiety is associated with disorders in the right hemisphere and other frontal, temporal, and occipital lobe disorders (Robert. F. Scmidt. Human physiology , p366; Min Sung-gil, pp. 238-240). .

Research on the treatment of anxiety and depression has been carried out with the reevaluation of old drugs, the expansion of indications, and the development of new drugs (especially the development of serotonin reuptake inhibitors). The ideal treatment for anxiety and depression is to calm the patient without causing excessive drowsiness and physical or mental dependence. Current clinically effective therapies have the disadvantage of having to be careful about their use with side effects such as drowsiness and withdrawal, along with anti-anxiety and antidepressant effects.

Representative drugs currently used for anxiety and depression are benzodiazepine, diazepam, oxazepam, prazepam, lorazepam, alprazolam, helazepam. And clonazepam, which are also used as sedative and sleep-inducing agents (Yoon Do-jun. Side effects of psychiatric drugs, Korean Medical Association, 38 (10) , pp1196-1202, 1995). For benzodiazepines are the most commonly used, a Cl ^_ passage adjacent increases the affinity of the GABA receptor representative inhibitory neurotransmitter of the central nervous system by opening more often there been shown to increase the permeability of Cl ^_ ion exhibits a rapid effect habitual And it is addictive and may cause symptoms such as relapse or withdrawal if not taken carefully according to a doctor's prescription, and may cause side effects such as drowsiness, ataxia, orthostatic hypotension, respiratory depression, headache, chronic sleep disorders and liver disease. (Mary J. et al., Pharmacology, 2nd edition , Lipincott Williams & Wilkins. Pp89-93, 2000).

In oriental medicine, depression, anxiety, and nervousness are caused by blood decay, gastrointestinal and liver, heart and nasal fever. Blows, damons, terrors, cramps, frenzy, and rage appear. In modern medicine, panic disorder, which causes symptoms such as major intestinal tract, air mass, splitting stage, and alertness, and ovulation caused by severe stress due to strong stress, Are included in categories of mental nervous system diseases such as depression and anxiety. In oriental medicine, these mental nervous system diseases are mainly treated with a group of drugs called anxin drugs. These drugs reduce anxiety and have sedative hypnotic and anticonvulsant effects (松本 克 産, synergistic consideration of neurosis. Medicine, 5 , pp65-68, 1986; Kim Jung-je, Assistant Director of Oriental Medicine, Sung-bo, pp228-232, 1997).

On the other hand, the inventors have confirmed that the drug to remove heat from the herbal medicine in addition to the Anxin drug (Ru Jonghun, et al., Anti-anxiety effect of gold using elevated plus-maze in rats. J Korean Journal of Pharmacognosy, 35 , pp22) -27, 2004). However, the anti-anxiety and antidepressant effects of bamboo leaf, which is a blue blood metabolism drug, are not known.

About 280 kinds of bamboo are known around the world as flowers and plants. About 70 kinds of bamboo are grown or grown in Korea. There are 11 varieties of varieties, including daedae, wangdae (seam porridge), jongjongju (juksundae), ojuk, dough, island, haejangjuk (shinwoodae), gatdae, walnut, mountain porridge, and daedae.

According to Dongbobogam, herbaceous tree, and new agricultural plant, bamboo has excellent effect in treating stroke and hypertension. Efficacy in the treatment of hypertension, atherosclerosis, and cardiovascular diseases. It is being used (Information Subsidiary and Shin Mingyo, Hyangdae Dictionary, p207, 1998).

In addition, bamboo, shells, branches, leaves, shoots, endothelial killing and the like have been used as a traditional herbal medicine. In particular, leaf (bamboo leaf) has been used for folk remedies such as heat lowering, stroke and hypertension because of its bitter taste and nature, and it is known to have bactericidal, antifungal and anticancer effects. In addition, the bamboo extract heated by heating has excellent effects in treating palsy and hypertension in Chinese herbal medicine dictionary, Dongbobogam, herbal herb, etc. Introduced as a good crop.

However, there is no teaching or description anywhere in the literature regarding the use of bamboo leaf extract in connection with the therapeutic and prophylactic effects of cerebral nervous system-related mental disorders such as anxiety, depression or nervousness.

Accordingly, the present inventors have recognized the problems in the prior art in the treatment and prevention of mental disorders such as anxiety, depression and neurological hypersensitivity, and have drugs that exhibit anti-anxiety and antidepressant effects without side effects such as addiction, drowsiness, chronic sleep disorders and headaches. The present invention was completed by confirming the excellent effect of bamboo leaf extract through research and development to develop.

An object of the present invention to provide a pharmaceutical composition and health functional food for the treatment and prevention of cerebral nervous system-related mental diseases containing bamboo leaf extract.

In accordance with the above object, the present invention provides a pharmaceutical composition for the treatment and prevention of cerebral nervous system-related mental diseases, including bamboo leaf extract.

The cerebral nervous system-related mental diseases include anxiety, depression, and nervousness.

In addition, the bamboo leaf extract includes water, ethanol, lower alcohols such as methanol or mixed solvents thereof, preferably water, 50%, 70%, 95% ethanol, more preferably 70% ethanol extracted.

The jukyeop is sanjuk (Sasa, Sasa borealis Makino), God vs. (Sasa coreana Nakai), two (Sasa japonica Makino), seomdae (Sasa borealis var. Gracilis), Jeju Sasa (Sasa palmata Nakai) Judges (SaSa) in such of bamboo leaves, Timber bamboo (Phyllostachys bambusoides SIEB. et Zucc), Black bamboo (Phyllostachys nigra MUNRO), somdae (bunjuk, Phyllostachys nigra MUNRI var. henonis STAPF), Timber bamboo, such as Phyllostachys edulis (maengjongjuk, Phyllostachys pubescens MAZEL ex H. de LEH) (Phyllostachys) contains the leaves of the genus Bamboo.

Hereinafter, the present invention will be described in detail.

Bamboo leaf extract of the present invention can be obtained as follows.

The bamboo leaves of the present invention, preferably bamboo shoots or bamboo leaves of the royal genus, more preferably cut off and wash the leaves of mountain rice porridge, sindae, daedae, island, Jeju bori, pongdae, daedae, bamboo porridge or bamboo shoots About 1 to 15 times the dry weight of the dried bamboo leaves, preferably about 10 to 15 times the volume of water, lower alcohols such as methanol or ethanol, or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10. Hydrothermal extraction, cold immersion, preferably in water, 70%, 95% ethanol at an extraction temperature of 20-100 ° C., preferably 90-100 ° C. for about 0.5 hours to 2 days, preferably 1 hour to 1 day. Extraction, reflux cooling extraction or ultrasonic extraction was repeated one to five times, preferably two to three times, and the resultant was filtered under reduced pressure and concentrated under reduced pressure, and then the extracted residue was vacuumed. Freeze gun Group can be obtained by drying a jukyeop extract soluble in a lower alcohol or a mixed solvent such as water, ethanol, methanol.

The present invention provides a pharmaceutical composition for the prevention and treatment of cerebral nervous system-related mental diseases containing bamboo leaf extract obtained by the above production method as an active ingredient.

In order to examine the efficacy of bamboo leaf extract obtained by the above method as a therapeutic agent for brain disorders related mental disorders, ICR mice were treated with bamboo leaf extract to observe behavioral patterns in elevated cross-maze (Elevated Plus-Maze (EPM)). As a result, it was confirmed that the anti-anxiety and anti-depressant effect is excellent.

The pharmaceutical composition for the prevention and treatment of cerebral nervous system related mental diseases of the present invention, the extract comprises 0.1 to 50% by weight based on the total weight of the composition.

Pharmaceutical compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

Pharmaceutical dosage forms of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.

Pharmaceutical compositions comprising extracts according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Carriers, excipients and diluents that may be included in the composition comprising the extract or compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. Or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 20 to 40 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

The extract of the present invention can be administered to mammals such as mice, mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

The present invention provides a health functional food comprising the extract and a food acceptable food supplement additive exhibiting a prophylactic effect of a cerebral nervous system related disease. Examples of the food to which the extract of the present invention can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.

It may also be added to foods or beverages for the purpose of preventing the effects of mental disorders related to the nervous system. At this time, the amount of the extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1g based on 100 ml. have.

Health functional food of the present invention includes the form of tablets, capsules, pills, liquids and the like.

The health functional beverage composition of the present invention is not particularly limited to other ingredients except for having the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extracts or compounds of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the extract or compound of the present invention.

Below, The invention is illustrated in detail by the following examples and experimental examples.

However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.

Example 1 Preparation of Bamboo Leaf Extract

1-1. Preparation of Bamboo Leaf Hot Water Extract

After washing 500g of bamboo leaves (leaves of cotton rod) purchased from Gyeongdong market, washed with clean water, dried in the shade for 10 days, powdered, and then extracted with 5 liters of secondary distilled water and reflux-cooled at 90-100 ℃ for about 2 hours. After filtration, lyophilization in a freeze dryer yielded 20 g of rice extract (4% yield).

1-2. Preparation of Bamboo Leaf Ethanol Extract

After washing 500g of bamboo leaves (leaves of cotton rod) purchased from Gyeongdong market, washed with clean water, dried naturally in the shade for 10 days, powdered, and 2.5L of 70% ethanol was added and repeated twice with an ultrasonic extractor for about 1 hour. Ultrasonic extraction, followed by filtration and drying under reduced pressure gave 25 g (yield 5%).

Reference Example 1. Laboratory Animals and Reagents

1-1. Laboratory animals

 Six-week-old ICR mice (28-32 g) were supplied from Samtako (Osan, Gyunggi-Do, Korea) and used for 5 days in a clean cage at Kyung Hee University. In addition, water and feed were freely consumed, and the temperature (23 ± 2 ° C), humidity (55 ± 10%) and contrast period (12 hours) were automatically adjusted.

1-2. reagent

Busspirone was purchased from Sigma-Aldrich and the other reagents were the highest commercially available.

Experimental Example 1. Anti-anxiety effect of bamboo leaf extract using EPM

Elevated Plus-Maze (EPM) described in the reference (GR Dawson, Trends Pharmacol. Sci., 16 , pp33-36, 1995) was used as a method of identifying behaviors associated with anxiety.

1 mg / kg of buspirone, a positive control drug, was administered to the ICR mice 30 minutes before the experiment, and bamboo leaf extracts were orally administered in 50, 100, 200, 400 and 800 mg / kg doses of saline solution, respectively. Was to be terminated 1 hour before the experiment. The negative control group was orally administered 0.9% NaCl. At this time, each group was 10-12.

After drug administration, anti-anxiety effect was measured using a self-made EPM, and the EPM was installed in a dark room with indirect lighting (20 Lux). The length of the EPM arm was crossed at a right angle of 30 cm, one side was covered with synthetic resin, and the wall height was 20 cm, and the other was left open. The width of each plate was 7 cm, the central platform was 7 cm and 7 cm, and the arm was used at a distance of 50 cm from the ground. The head of the mouse was placed toward the closed arm on the central platform of the maze and then allowed to explore the maze freely. The behavior was observed for 5 minutes, and the time spent on the open and closed arms of the mouse, the number of entrances and the total movement distance of each arm were measured using the EthoVision program (Noldus Ingormation Technology, Wageningen, Netherlands). Anxiety effect was measured.

All experimental results were statistically analyzed using one way analysis of variance (ANOVA), and if significant, the significance test was conducted at P < 0.05 level using the SNK method (Student-Newman-Keuls Test). Was carried out.

1-1. Measure change in stay time

When the experimental animals stayed in the open space, the negative control group showed 31.34 ± 3.97 seconds, whereas the positive control group, which was 96.17 ± 11.44 seconds ( P <0.001), showed a significant increase. In addition, the experimental group administered with bamboo leaf extract at 200, 400 and 800 mg / kg, respectively, showed 65.48 ± 5.56 seconds, 88.34 ± 6.30 seconds and 67.42 ± 7.16 ( P <0.001), respectively, about 108.93%, 181.83 compared to the negative control group. %, 115.12% was found to increase significantly.

On the other hand, in the time of staying in the closed space, the negative control group was 163.62 ± 5.22 seconds, whereas in the buspyron administration group appeared to be 116.73 ± 9.35 seconds, significantly decreased ( P <0.001). For experimental groups administered bamboo leaf extract at 200, 400 and 800 mg / kg, respectively, the negative control group was 107.51 ± 3.83 seconds ( P <0.001), 99.97 ± 10.27 seconds ( P <0.001) and 128.13 ± 4.08 ( P <0.01), respectively. When compared with, it was confirmed that the significant decrease of about 34.17%, about 38.78% and about 21.55%. In addition, it was observed that the time stayed in the closed space decreased with increasing dose of bamboo leaf extract (see FIG. 1).

From the above results, the group administered with bamboo leaf extract was found to increase significantly in the open space and to decrease in the closed space it was confirmed that there is excellent anti-anxiety and antidepressant effect.

1-2. Change in the number of entry and exit

The number of accesses to the open space of the experimental animals was 15.38 ± 1.35 times in the control group, whereas the positive control group was 23.78 ± 1.71 times in the control group, which was significantly increased ( P <0.001). The experimental groups administered with bamboo leaf extract at 200, 400 and 800 mg / kg, respectively, were negative control group with 21.00 ± 1.09 ( P <0.01), 24.88 ± 1.48 ( P <0.001) and 23.70 ± 1.35 ( P <0.001), respectively. In comparison, a significant increase of about 36.54%, about 61.77% and about 54.10% was observed.

On the other hand, the number of entrances and exits of the closed space was 29.13 ± 0.91 times in the negative control group, whereas it was 21.80 ± 1.50 in the buspyron administration group, indicating a significant decrease ( P <0.001). The experimental groups administered with bamboo leaf extract at 200, 400 and 800 mg / kg, respectively, were 21.13 ± 0.97, 19.63 ± 0.78 and 20.11 ± 0.84 times ( P <0.001), compared with the negative control, about 27.46%, about 32.61% and A significant decrease of about 30.96% was observed (see Figure 2).

From the results, the group administered with bamboo leaf extract was found to significantly increase the number of entry and exit into the open space and decrease the number of entry and exit into the closed space was confirmed to have excellent anti-anxiety and antidepressant effect.

1-3. Locomotor activity measurement in open space

Locomotor activity of the mice was measured in an open field test to determine if the effect of the drug was due to a simple change in motility.

Locomotor activity was measured in a self-manufactured open space test box, which was made 41.5 cm wide, 41.5 cm long and 43 cm high, and measured for 5 minutes, one animal per box. It was.

As a result of the experiment, the total moving distance of the negative control group and the positive control group (boospyron administration group) was 1837.47 ± 91.19 cm and 1731.44 ± 99.67 cm, respectively, and the experimental group administered with the bamboo leaf extract at the doses of 200, 400 and 800 mg / kg The moving distances were 1927.37 ± 74.99 cm, 1959.05 ± 124.25 cm, and 1910.90 ± 94.78 cm, respectively. In addition, the total travel distance in the EPM was 1604.11 ± 103.02 cm, 1426.01 ± 102.28 cm in the control group and the buspyron administration group. Bamboo leaf 200, 400 and 800 mg / kg administration group was moved 1483.89 ± 54.99 cm, 1544.03 ± 53.59 cm and 1542.16 ± 71.70 cm, respectively, and there was no significant difference between the control and bamboo leaf administration group. Accordingly, it could be confirmed that the results in Examples 1-1 and 1-2 were not due to a simple change in mobility.

Experimental Example 2. Acute Toxicity Test

2 g / kg of the bamboo leaf extract of Example 1 was orally administered to 10 mice of Reference Example 1-1, and the change was observed, but no death was observed. I could not find more than one. Therefore, bamboo leaf extract of the present invention was confirmed to be a safe drug.

An example of the preparation of the pharmaceutical composition is exemplified below, which is intended to explain in detail rather than limit the present invention thereto.

Formulation Example 1 Preparation of Powder

According to the preparation method of powder in the pharmacopeia formulation, it is prepared in the following ingredient content per one packet.

Bamboo Leaf Extract 400 mg

Lactose 100 mg

Talc 10 mg

Formulation Example 2 Preparation of Tablet

According to the preparation method of tablets in the pharmacopeia formulation, it is prepared in the following component content per tablet.

Bamboo Leaf Extract 400 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

Formulation Example 3 Preparation of Capsule

According to the preparation method of capsules in the pharmacopeia formulation, it is prepared in the following component content per capsule.

Bamboo Leaf Extract 400 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

Formulation Example 4 Preparation of Injection

According to the preparation method of injectables in the pharmacopeia formulation, it is prepared in the following component contents per ampoules (2 ml).

Bamboo Leaf Extract 400 mg

Appropriate sterile distilled water for injection

pH adjuster

Formulation Example 5 Preparation of Liquid

According to the preparation method of the liquid formulation in the Pharmacopoeia General Formulation, it is prepared in the following component content per 100 ml of the liquid formulation.

Bamboo Leaf Extract 1g

10 g of isomerized sugar

5 g of mannitol

Purified water

Formulation Example 6 Preparation of Healthy Food

Bamboo Leaf Extract 1000mg

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B ₁ 0.13 mg

Vitamin B ₂ 0.15 mg

Vitamin B ₆ 0.5 mg

0.2 μg of vitamin B ₁₂

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

Folate 50 ㎍

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation Example 7 Preparation of Healthy Drink

Bamboo Leaf Extract 1000mg

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components according to a conventional healthy beverage manufacturing method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.

Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

The composition containing the bamboo leaf extract has an anti-anxiety and antidepressant effect and thus can be usefully used for the treatment of mental diseases caused by abnormalities of the cranial nervous system.

Claims (8)

A pharmaceutical composition for the treatment and prevention of cerebral nervous system-related mental diseases, including bamboo leaf extract. The pharmaceutical composition according to claim 1, wherein the bamboo leaf extract is an extract available in a lower alcohol such as water, ethanol, methanol or a mixed solvent thereof. The pharmaceutical composition according to claim 1 or 2, wherein the bamboo leaves are leaves of bamboo of the genus Sasa or Phyllostachys. 4. The method of claim 3, Sasa (Sasa) in bamboo sanjuk (Sasa, Sasa borealis Makino), god for (Sasa coreana Nakai), two (Sasa japonica Makino), seomdae (Sasa borealis var. Gracilis), Jeju Sasa (Sasa palmata Nakai) is a pharmaceutical composition. According to claim 3, Phyllostachys genus bamboo is Phyllostachys bambusoides SIEB. Et Zucc, Phyllostachys nigra MUNRO, Cotton wool ( Phyllostachys nigra MUNRO var. Henonis STAPF) or Bamboo shoots ( Phyllostach AZEL pubes) ex H. de LEH.) pharmaceutical composition. The pharmaceutical composition according to any one of claims 1 to 5, wherein the neurological disorders related to the nervous system are anxiety, depression and nervousness. A dietary supplement comprising a bamboo leaf extract and a food acceptable food supplement. The dietary supplement according to claim 7, which is a tablet, pill, capsule or liquid.

Images